December 1, 2016EuroIntervention23 citationsOpen Access
DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial
View Full Paper
Structured PICO
Does the DESyne novolimus-eluting coronary stent reduce device- and patient-oriented events compared to the Endeavor zotarolimus-eluting coronary stent?
P
Population
Patients undergoing coronary stenting (EXCELLA II trial)
I
Intervention
DESyne novolimus-eluting coronary stent (NES)
C
Comparator
Endeavor zotarolimus-eluting coronary stent
O
Outcome
Incidence of device- and patient-oriented eventscomposite
The DESyne novolimus-eluting stent demonstrated significantly lower device- and patient-oriented events compared to the Endeavor zotarolimus-eluting stent at 5 years, though larger studies are needed to confirm clinical outcomes.
Limitations
- Not adequately powered for clinical outcomes
Abstract
At five-year follow-up, the incidence of device- and patient-oriented events was significantly lower in the NES group. Further studies, adequately powered for clinical outcomes, are warranted.